{"filings":[{"id":2078884,"accession_number":"0001724521-26-000042","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2026-08-05T20:07:48+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcus Q2 net loss $91M, revenue $41M; casdatifan pipeline advances with new collaborations","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $91M in Q2 2026 vs. $0 in Q2 2025; revenue fell to $41M from $160M.","Cash $775M at June 30; expects ~$600M year-end; runway to at least H2 2028.","Casdatifan: multiple data readouts H2 2026; new collaborations with BMS, Summit, AVEO.","Gilead relinquishes three board seats; PACIFIC-8 Phase 3 study discontinued.","Quemliclustat gets EU orphan drug designation; PRISM-1 Phase 3 results due H1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1027557,"accession_number":"0001724521-26-000037","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2026-06-12T20:12:40+00:00","items":["5.07"],"status":"ready","headline":"Arcus Biosciences stockholders elect four Class II directors, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Class II directors: Dietmar Berger (85.9M for), David Lacey (86.0M), Nicole Lambert (92.7M), Johanna Mercier (85.9M); ~13.6M broker non-votes.","Ratified Ernst & Young as auditor for FY2026: 112.9M for, 4.8M against, 0.2M abstain.","Advisory say-on-pay approved: 94.9M for, 9.3M against, 29.7K abstain; 13.6M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95008,"accession_number":"0001724521-26-000032","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcus Q1 net loss $128M, cash $876M; discontinues Phase 3 STAR-121 in NSCLC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $128M for Q1 2026 vs $112M Q1 2025; revenue $17M down from $28M.","Cash $876M at Mar 31, 2026, down from $1.0B at Dec 31, 2025; expect ~$600M year-end, runway to H2 2028.","Discontinued Phase 3 STAR-121 (domvanalimab) in NSCLC after futility analysis (OS not improved vs pembrolizumab+chemo).","Pipeline: casdatifan Phase 3 PEAK-1 enrolling; 1L Phase 3 initiation expected year-end; new I&I candidate AB102 entering clinic Q3 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":17000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95007,"accession_number":"0001724521-26-000021","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Arcus discontinues Phase 3 STAR-121 NSCLC trial; Gilead lets option rights lapse","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["STAR-121 evaluating domvanalimab + zimberelimab + chemo vs pembro + chemo in 1L metastatic NSCLC stopped by IDMC for futility.","Zimberelimab + chemo showed comparable overall survival vs pembro + chemo; trial discontinued despite that.","Gilead declines option continuation payment; option period ends July 14, 2026; loses rights to CCR6, CD89, CD40L programs.","Gilead retains time-limited options for AB801 (AXL inhibitor), AB598 (anti-CD39), AB102 (MRGPRX2 antagonist), and TNF small molecule.","Arcus retains full rights to casdatifan program except Taiho territories (Japan and certain Asian countries)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107774,"accession_number":"0001724521-26-000014","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Arcus Biosciences COO Jennifer Jarrett resigns effective March 30, 2026; advisory role through June 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["COO Jennifer Jarrett resigns effective March 30, 2026; departure not due to any disagreement with company.","Separation agreement includes advisory services through June 30, 2026, and extends post-termination option exercise period to 12 months.","Agreement includes a standard release of claims; final separation agreement to be filed with next 10-Q.","No replacement for COO position has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107773,"accession_number":"0001724521-26-000007","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcus Biosciences reports Q4 net loss $106M; casdatifan shows 45% cORR in late-line kidney cancer","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net loss $106M vs $94M YoY; revenue $33M; cash, equivalents & marketable securities $1.0B.","Casdatifan 100mg QD in late-line ccRCC: confirmed ORR 45.2%, median PFS 15.1 months (Jan 30, 2026 cut).","Full-year 2026 GAAP revenue guidance $45-55M; R&D expenses expected to decrease meaningfully.","Phase 3 PEAK-1 (casdatifan + cabozantinib) enrolling globally; 1L Phase 3 planned by end 2026.","First inflammation program (oral MRGPRX2 antagonist) to enter clinic in 2026; oral TNF inhibitor in late 2026/early 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":247000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124158,"accession_number":"0001724521-25-000122","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Arcus Biosciences amends loan agreement to access up to $150M tied to clinical and FDA milestones","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["First Amendment to Loan and Security Agreement with Hercules Capital dated December 18, 2025.","Up to $50M available after announcement of Phase 3 data supporting FDA filing; $50M after FDA approval.","$50M available at company's sole option through March 2026 and September 2026 ($25M each).","Maturity extended to September 1, 2030.","Performance covenants apply if draws exceed $200M: market cap ≥ $1.5B or cash/revenue thresholds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124157,"accession_number":"0001724521-25-000120","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Arcus ends Phase 3 STAR-221 domvanalimab study on futility; no OS benefit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 STAR-221 of domvanalimab + zimberelimab + chemo vs nivolumab + chemo stopped for futility after IDMC review.","Domvanalimab combo did not improve overall survival vs nivolumab + chemo; safety profile similar.","Phase 2 EDGE-Gastric also discontinued; company and Gilead communicating with investigators.","R&D focus shifts to HIF-2a inhibitor casdatifan and small molecule inflammation programs; MRGPRX2 inhibitor clinical entry expected 2026.","Cash runway expected to fund operations until at least second half 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124156,"accession_number":"0001193125-25-262589","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arcus Biosciences closes public offering of 15.76M shares, net proceeds ~$269.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 15,755,000 shares at $18.25 per share including full exercise of underwriters' option.","Net proceeds of approximately $269.7 million after discounts and estimated expenses.","Underwriters led by Leerink Partners LLC and Goldman Sachs & Co. LLC.","Offering closed on November 3, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124155,"accession_number":"0001724521-25-000114","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcus Biosciences reports Q3 2025 net loss $135M; casdatifan shows 12.2 mo mPFS in late-line kidney cancer","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $135M for Q3 2025 vs $92M in Q3 2024; revenue $26M vs $48M.","Casdatifan pooled analysis (n=121) showed 12.2 months median PFS and 35% ORR at 100mg dose in late-line ccRCC.","Taiho exercised option for casdatifan in Japan/Asia for option payment, milestones, and royalties.","Cash and equivalents $841M; funded through PEAK-1 Phase 3 readout.","Domvanalimab + zimberelimab + chemo showed 26.7 months median OS in EDGE-Gastric study."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":214000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124154,"accession_number":"0001724521-25-000109","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Arcus Bio's EDGE-Gastric Ph2 shows median OS 26.7 months; ORR 59%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median OS 26.7 months (90% CI: 18.4, NE) for all patients (n=41); PD-L1 high subgroup NE.","Confirmed ORR 59% (24/41) per RECIST v1.1; 62% in PD-L1 positive and 69% in PD-L1 high subgroups.","Median PFS 12.9 months overall; 24-month OS rate 50.2% and PFS rate 25.9%.","Median follow-up 26.4 months; median time on domvanalimab+zimberelimab+chemo was 49 weeks.","No unexpected safety signals; immune-mediated TEAEs in 22% of patients, infusions reactions in 7%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124153,"accession_number":"0001724521-25-000107","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Arcus reports ARC-20 Phase 1/1b data: pooled ORR 31%, median PFS 12.2 mo; unveils 5 I&I preclinical programs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ARC-20 pooled analysis (n=121) in ccRCC: 31% confirmed ORR [95% CI 23-40], median PFS 12.2 mo (9.4-20.6).","50 mg QD cohort showed 36% ORR (incl. pending) and median PFS 19.2 mo; 100 mg QD showed 42% ORR (incl. pending).","Safety: Grade≥3 anemia 41%, hypoxia 11%; discontinuation rate 3%; no unexpected signals as of Aug 15, 2025 DCO.","Five new preclinical programs disclosed: MRGPRX2, TNFR1, CCR6, CD89, CD40L; first clinical study targeted in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140827,"accession_number":"0001724521-25-000099","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcus Biosciences Q2 2025 rev $160M (incl $143M one-time), net income breakeven; casdatifan Phase 3 trials initiated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents & marketable securities: $927M at June 30, 2025 (Dec 31, 2024: $992M).","Q2 2025 revenue $160M vs $39M YoY, driven by $143M cumulative catch-up from etrumadenant program pause.","R&D expenses $139M (vs $115M Q2 2024); CMC costs expected elevated through Q3, then decline from Q4.","PEAK-1 (Phase 3 casdatifan + cabozantinib) and eVOLVE-RCC02 (Phase 1b/3 with AstraZeneca) initiated in ccRCC.","Quemliclustat granted FDA Orphan Drug Designation for pancreatic cancer; PRISM-1 enrollment completion expected Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":188000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158569,"accession_number":"0001724521-25-000078","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Arcus annual meeting elects directors, ratifies E&Y, approves say-on-pay; board revises director comp","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All four Class I director nominees elected with >86M votes each (broker non-votes ~8.6M).","Ernst & Young ratified as auditor for FY2025 with 96.8M votes for (96.3% of votes cast).","Advisory 'say-on-pay' approved with 84.8M for (93.9% of votes cast excluding abstentions).","Board revised Non-Employee Director Compensation Program: $50k cash retainer, $750k initial equity, $400k annual equity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158568,"accession_number":"0001724521-25-000066","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["7.01","8.01"],"status":"ready","headline":"Arcus reports 46% confirmed ORR for casdatifan + cabozantinib in ccRCC post-immunotherapy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1/1b ARC-20 interim analysis shows 46% cORR (11/24) per RECIST v1.1; median follow-up 5.3 months.","Response includes 1 complete response (4%) and 10 partial responses (42%); 50% had stable disease.","Safety evaluable population (n=42) showed acceptable safety profile with no new unexpected risks or overlapping toxicity.","Study evaluates casdatifan 100mg QD plus cabozantinib 60mg QD in patients with ccRCC who progressed on prior immunotherapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158567,"accession_number":"0001724521-25-000061","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcus Q1 net loss widens to $112M; cash $1.0B; casdatifan Phase 3 to start Q2","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue fell to $28M from $145M YoY; full-year 2025 revenue guidance $75M-$90M.","Net loss of $112M vs $4M in Q1 2024; R&D expenses rose to $122M from $109M.","Cash, equivalents, marketable securities $1.0B; sufficient to fund through initial pivotal readouts.","Phase 3 PEAK-1 trial of casdatifan + cabozantinib in ccRCC expected to initiate Q2 2025.","FDA feedback on etrumadenant supports registrational path but Arcus not pursuing Phase 3 now."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":28000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176965,"accession_number":"0001724521-25-000039","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcus Q4 2024 net loss $94M; casdatifan shows best-in-class potential in ccRCC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Revenue $36M for Q4 2024 ($31M Q4 2023); net loss widened to $94M from $81M.","Cash & marketable securities $992M as of Dec 31, 2024, up from $866M year-end 2023.","Casdatifan monotherapy in IO/VEGFR-TKI experienced ccRCC achieved 30%+ ORR, 9.7-month median PFS (50mg BID).","Phase 3 PEAK-1 (casdatifan + cabozantinib vs cabo in post-IO ccRCC) expected to initiate Q2 2025.","Domvanalimab/zimberelimab Phase 3 STAR-221 top-line data for 1L upper GI cancers expected 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176964,"accession_number":"0001193125-25-029591","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arcus Biosciences raises ~$141.6M in public offering of 13.6M shares at $11.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offered 13,636,364 shares at $11.00/share, yielding ~$141.6M net proceeds after expenses.","Proceeds to fund R&D activities, including clinical development of casdatifan, manufacturing, and general corporate purposes.","Offering closed on Feb 19, 2025; underwritten by Goldman Sachs and Leerink Partners.","Shares sold under existing shelf registration statement (Form S-3) filed with the SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176963,"accession_number":"0001193125-25-028110","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"Arcus reports $992M cash; Gilead opts out of casdatifan; ARC-20 data shows ORR 25-33%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, cash equivalents and marketable securities of $992M as of Dec 31, 2024.","Gilead's exclusive option for casdatifan expired without exercise; Arcus retains full global rights.","ARC-20 in ccRCC: 50mg BID median PFS 9.7 months, ORR 25%; 100mg QD ORR 33%.","Disease control rate 81-87% across cohorts; median DoR not reached; safety acceptable.","All but two of 26 responders remained on treatment; one discontinuation due to anemia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176962,"accession_number":"0001724521-25-000024","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Arcus Biosciences appoints Dietmar Berger to board replacing Merdad Parsey","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Merdad Parsey resigned from Arcus board effective upon Gilead's new director designee; he left Gilead.","Dietmar Berger, Gilead's CMO since Jan 2025, appointed as Class II director to fill vacancy.","Dr. Berger will not receive compensation for board service; Arcus will enter standard indemnification agreement.","Changes made pursuant to Amended and Restated Investor Rights Agreement between Arcus and Gilead."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176961,"accession_number":"0001724521-25-000005","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Arcus appoints Richard Markus as CMO; Dimitry Nuyten departs Jan 31, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard Markus, M.D., Ph.D., named Chief Medical Officer, effective January 31, 2025.","Dimitry Nuyten, M.D., Ph.D., will depart from Arcus on the same date.","Dr. Nuyten eligible for lump-sum severance of 12 months base salary, 12 months COBRA, and 2024 bonus.","Separation agreement details described; final agreement to be filed after execution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193756,"accession_number":"0001724521-24-000159","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcus Q3 net loss $92M; casdatifan shows 34% ORR, domvanalimab 36% risk reduction","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $92M vs $71M YoY; revenue $48M (up from $32M) on $41M license and development services.","Cash, equivalents and securities $1.1B, providing runway into mid-2027; year-end expected $950M-$985M.","Casdatifan 100mg cohort: 34% ORR (25% confirmed), 19% primary progression, median PFS not reached.","Domvanalimab+zimberelimab reduced risk of death by 36% (HR=0.64) vs zim in 1L NSCLC; median OS not reached.","Clinical collaboration with AstraZeneca to test casdatifan + volrustomig in IO-naive ccRCC."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":232000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193755,"accession_number":"0001724521-24-000153","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["7.01","8.01"],"status":"ready","headline":"Arcus reports casdatifan interim data: 34% ORR in heavily pre-treated ccRCC patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORR 34% (11/32) in efficacy-evaluable patients at 100 mg dose; confirmed ORR 25% (8/32).","Disease control rate 81%; median progression-free survival not reached (data cutoff Aug 30, 2024).","Patient population heavily pre-treated: 52% had ≥3 prior lines; 61% intermediate IMDC risk.","Grade 3 TEAEs related to casdatifan were 42% (anemia 36%, hypoxia 9%); no deaths or life-threatening events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210074,"accession_number":"0001724521-24-000144","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2024-08-27T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Arcus Biosciences secures up to $250M term loan facility from Hercules Capital; initial $50M funded","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial $50M funded; additional $50M available at company's option through Jun 2025 and another $50M through Mar 2026; final $100M at lenders' option.","Interest rate = greater of Prime Rate + 1.95% or 10.45% p.a.; interest-only payments until Sep 2028, extendable 12 months if FDA approves BLA/NDA.","Loans mature Sep 2029, extendable 12 months upon two of three milestones: phase 3 starts for casdatifan, quemliclustat, or etrumadenant.","Covenant: if mkt cap ≤ $1.2B, maintain Qualified Cash ≥ 50% of outstanding principal; threshold reduces to 40% or 35% upon milestones.","Prepayment premium 3% (yr1), 2% (yr2), 1% (thereafter); end-of-term charge 7.75%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210073,"accession_number":"0001724521-24-000136","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcus reports Q2 2024 net loss $93M, cash $1.0B; casdatifan data due Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $39M (up from $29M in Q2 2023); net loss $93M vs $75M year-over-year.","Cash, cash equivalents and marketable securities $1.0B, sufficient into 2027; expects $885-925M by year-end 2024.","Casdatifan 100mg ccRCC expansion ORR data expected Q4 2024; PEAK-1 Phase 3 study start H1 2025.","STAR-221 (domvanalimab+chemo) completed enrollment; STAR-121 (NSCLC) expected to complete enrollment in 2024.","Taiho exercised option for quemliclustat in Japan/Asia; Phase 3 PRISM-1 pancreatic cancer to start early 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":184000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228301,"accession_number":"0001724521-24-000101","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Arcus Biosciences adopts amended director compensation; annual meeting passes all proposals","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New non-employee director compensation: $45,000 annual cash retainer; $25,000 extra for Lead Independent Director.","Initial equity award: ~$750,000 grant-date value, 2/3 stock options and 1/3 RSUs, vesting over 3 years.","Annual equity award: ~$400,000 grant-date value, vests fully in 12 months or until next annual meeting.","Annual meeting results: all three Class III directors elected; Ernst & Young ratified; say-on-pay approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228300,"accession_number":"0001724521-24-000099","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["7.01","8.01"],"status":"ready","headline":"Arcus reports Phase 2 EDGE-Gastric interim data: median PFS 12.9 months, ORR 58.5% in upper GI cancers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median PFS of 12.9 months (95% CI 9.8–13.8) across 41 patients in the domvanalimab+zimberelimab+chemo arm.","Confirmed ORR 58.5%, with 3 complete responses and median DOR of 12.4 months (95% CI 9.9–NE).","PD-L1-high subgroup (TAP ≥5%) showed median PFS 13.8 months and ORR 68.8% (n=16).","No unexpected safety signals; infusion-related reactions in 19.5% of subjects, mostly chemotherapy-related.","Data cutoff March 12, 2024; results posted to company website on June 2, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228299,"accession_number":"0001724521-24-000096","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ARC-9 interim analysis: EZFB combo improves PFS (HR 0.27) and OS (HR 0.37) vs regorafenib in 3L mCRC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cohort B (n=112) met primary endpoint: PFS HR 0.27 (p<0.0001), median 6.2 vs 2.1 months.","OS key secondary: HR 0.37 (p=0.0003), median OS 19.7 vs 9.5 months favoring EZFB.","ORR 17.3% for EZFB vs 2.7% for regorafenib; safety profile consistent with FOLFOX/bev.","Data selected for oral presentation at 2024 ASCO Annual Meeting on June 2, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228298,"accession_number":"0001724521-24-000090","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcus Q1 revenue jumps to $145M, net loss $4M; pipeline advances with ASCO presentations and Phase 3 enrollments","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $145M vs $25M YoY, including $135M license revenue from Gilead collaboration amendments.","Net loss $4M vs $80M YoY; cash $1.1B at quarter end; year-end 2024 cash expected $870-920M.","R&D expenses $109M (up from $81M); $20M impairment charge for facility sublease.","Two oral presentations at ASCO 2024: EDGE-Gastric (domvanalimab) and ARC-9 (etrumadenant) in GI cancers.","Phase 3 STAR-221 enrollment expected mid-2024; STAR-121 H2 2024; first Phase 3 for casdatifan in ccRCC planned H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":145000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247023,"accession_number":"0001724521-24-000050","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcus Q4 net loss $81M; cash to $1.2B after Gilead; streamlines TIGIT program; casdatifan shows promise","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $81M in Q4 2023 ($307M full year); revenue $31M Q4 2023 vs $34M Q4 2022.","Pro forma cash $1.2B after $320M equity investment from Gilead in Jan 2024; funding into 2027.","Discontinued ARC-10 Phase 3 in PD-L1-high NSCLC; accelerating STAR-121; planning STAR-131 in perioperative NSCLC.","Casdatifan (HIF-2a) Phase 1 data: 20 mg dose achieved similar EPO suppression as 120 mg belzutifan; no DLTs.","Quemliclustat in pancreatic cancer: median OS 15.7 months in pooled ARC-8 analysis; Phase 3 planned early 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":117000000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247022,"accession_number":"0001724521-24-000034","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2024-01-30T23:59:59+00:00","items":["1.01","3.02","5.02","8.01","9.01"],"status":"ready","headline":"Gilead invests $320M in Arcus at $21/share; collaboration amended to accelerate anti-TIGIT program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gilead purchases 15.2M shares for $320M at $21/share, increasing ownership to 33%.","Collaboration reprioritized: focus on Phase 3 STAR-121 (lung) and STAR-221 (GI); ARC-10 discontinued.","New Phase 3 STAR-131 registrational study for domvanalimab + zimberelimab in lung cancer planned.","Johanna Mercier (Gilead CCO) appointed to Arcus board; two prior Gilead designees resign.","Quemliclustat pancreatic cancer study becomes Arcus-independent; cash runway extended into 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264463,"accession_number":"0001724521-23-000018","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcus Biosciences Q3 net loss $71M; cash $950M; domvanalimab and AB521 updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $71M in Q3 2023 vs $65M in Q3 2022; R&D expenses rose to $82M from $77M.","Cash, cash equivalents and marketable securities $950M as of Sept 30, 2023, down from $1.1B at Dec 31, 2022; cash runway into 2026.","Revenue $32M in Q3 2023, primarily from Gilead collaboration, vs $33M in Q3 2022.","EDGE-Gastric Phase 2: domvanalimab + zimberelimab + chemo showed 80% ORR in PD-L1-high tumors; maturity PFS data expected H2 2024.","AB521 Phase 1/1b: PK/PD consistent with healthy volunteers; no DLTs; ccRCC dose-expansion near completion; efficacy data later in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":86000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281699,"accession_number":"0000950170-23-038757","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcus Q2 net loss $75M, cash $1.0B; deprioritizes etrumadenant in mCRPC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $1.0B vs $1.1B at Dec 2022; 2023 cash burn guided $290-325M; funding into 2026.","Q2 net loss $75M vs $67M YoY; revenue $29M vs $27M; R&D expenses $84M vs $70M.","Domvanalimab ARC-7 data: 33% PFS risk reduction for doublet vs PD-1 monotherapy at ~18-mo follow-up.","Etrumadenant in mCRPC deprioritized; ARC-6 analysis shows insufficient clinical benefit to warrant further investment.","Gilead collaboration expanded to inflammation; Arcus gets $35M upfront; Gilead bought 1M shares at $19.26, raising stake to 19.9%."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":54000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300640,"accession_number":"0000950170-23-030273","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2023-06-28T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"Arcus Biosciences sells 1.01M shares to Gilead at $19.26 per share under amended purchase agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gilead to purchase 1,010,000 shares of Arcus common stock at $19.26 per share.","Agreement amends 2021 SPA; Gilead retains option to buy up to 35% of outstanding shares until July 2025.","Shares sold in unregistered transaction under Section 4(a)(2) to accredited investor Gilead.","Closing subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300639,"accession_number":"0000950170-23-028621","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2023-06-16T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Arcus Biosciences annual meeting results and revised director comp: $45k retainer, $750k initial equity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All four director nominees elected; Ernst & Young ratified as auditor; say-on-pay approved with ~92% for.","Board revised non-employee director compensation: annual cash retainer $45,000; additional committee chair retainers up to $25,000.","Initial equity award ~$750,000 (2/3 options, 1/3 RSUs) with 3-year vesting; annual award ~$400,000 with 12-month or next meeting vesting.","Compensation changes effective June 15, 2023, as detailed in Exhibit 10.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300638,"accession_number":"0000950170-23-026241","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2023-06-05T23:59:59+00:00","items":["7.01","8.01"],"status":"ready","headline":"Arcus ARC-7 Phase 2 data: domvanalimab arms reduce PFS risk 28-33% in NSCLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Doublet (domvanalimab+zimberelimab) showed 33% PFS risk reduction (HR 0.67) vs zimberelimab monotherapy in PD-L1≥50% NSCLC.","Median PFS: 5.4 mo (Z), 9.3 mo (DZ), 9.9 mo (EDZ); 12-month PFS rates 25%, 41%, 44%.","ORR: Z 30%, DZ 40%, EDZ 44%; median DoR not reached for DZ, 23.7 mo for EDZ.","No unexpected safety signals; infusion-related reactions low (4-12%) across arms.","Data from 150-patient randomized Phase 2 at ~18-month median follow-up."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300637,"accession_number":"0000950170-23-021988","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Arcus gets $35M upfront from Gilead to collaborate on up to 4 inflammatory disease targets","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront payment of $35M from Gilead Sciences under Amendment No. 2 to existing collaboration.","Arcus will conduct research on up to 4 jointly selected targets for inflammatory diseases.","If Gilead exercises early option on first 2 programs, Arcus eligible for up to $420M in option/milestone payments plus tiered royalties per program.","For other option exercises, parties co-develop/co-commercialize in US with cost and profit sharing.","Gilead has two prespecified time points to exercise options for each program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300636,"accession_number":"0000950170-23-019659","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcus Q1 net loss $80M, cash $1.0B; multiple Ph3 domvanalimab trials enrolling","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $25M (up from $18M YoY); net loss $80M vs $68M in Q1 2022.","Cash, equivalents and securities $1.0B; expected to fund operations into 2026.","Four Phase 3 and two Phase 2 trials enrolling for domvanalimab combinations in lung and GI cancers.","AB521 (HIF-2α inhibitor) dose-escalation enrolling 100mg; Phase 2 combo study in ccRCC expected Q3 2023.","Three new drug candidates advancing to clinic: AB598 (anti-CD39) Q2 2023, AB801 (Axl inhibitor) H2 2023, AB375 (KIT inhibitor) early 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":25000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320608,"accession_number":"0000950170-23-007320","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Arcus Biosciences appoints Alexander Azoy as Principal Accounting Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alexander Azoy appointed Principal Accounting Officer effective March 9, 2023.","Robert C. Goeltz II remains CFO but ceases as Principal Accounting Officer.","Azoy previously VP of Finance since Oct 2020; prior CFO at Sienna Biopharmaceuticals.","Azoy entered standard severance/change of control agreement and severance program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320607,"accession_number":"0000950170-23-005084","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcus Biosciences Q4 net loss $67M; ARC-7 domvanalimab combo doubles PFS to 12 months","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 net loss $67M vs net income $280M in Q4 2021; full-year net loss $267M vs net income $53M.","Revenue $34M in Q4 2022, down from $355M in Q4 2021; cash $1.1B, sufficient into 2026.","ARC-7 interim data: domvanalimab+zimberelimab mPFS 12.0 months vs 5.4 months for zimberelimab alone.","Four ongoing registrational Phase 3 studies for domvanalimab; updated ARC-7 data expected at ASCO June 2023.","AB521 (HIF-2a inhibitor) Phase 1/1b enrolling 50mg cohort; initial data expected late 2023 or early 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":112000000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338750,"accession_number":"0000950170-22-026760","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2022-12-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Arcus ARC-7 Phase 2: domvanalimab doublet cuts progression risk 45% vs. zimberelimab","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median PFS: doublet 12.0 mo, triplet 10.9 mo vs. monotherapy 5.4 mo (HR 0.55 and 0.65).","Confirmed ORR: doublet 41%, triplet 40% vs. monotherapy 27% in PD-L1≥50% 1L NSCLC.","Six-month PFS rate: doublet 65%, triplet 63% vs. monotherapy 43%; median follow-up ~12 mo.","No new safety signals; Grade≥3 AEs: doublet 47%, triplet 52% vs. monotherapy 58%.","Trial continues to monitor overall survival; data cutoff Aug 31, 2022 (n=149 safety, 133 efficacy)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338749,"accession_number":"0000950170-22-025712","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2022-11-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Arcus reports positive Phase 2 interim results for domvanalimab combo in NSCLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Fourth interim analysis of ARC-7 trial (n=133) shows domvanalimab-containing arms differentiate from zimberelimab monotherapy.","Clinically meaningful improvements in objective response rate, PFS, and six-month landmark PFS observed.","No unexpected safety signals; domvanalimab arms generally well tolerated with safety consistent with individual molecules.","Detailed results to be presented at ASCO Monthly Plenary Series on December 20, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338748,"accession_number":"0000950170-22-021219","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2022-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcus Biosciences Q3 net loss narrows to $64.9M, cash $1.19B, ARC-10 amended to compare domvanalimab vs pembro","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $33.6M (up from $9.5M); net loss $64.9M vs $78.0M prior year.","Cash and securities $1.19B as of Sep 30, 2022, funding operations into 2026.","ARC-10 Phase 3 amended: domvanalimab+zimberelimab vs pembrolizumab, no chemo arm, OS primary endpoint, n=600.","ARC-7 topline data on track for Q4 2022; presentation planned at 2023 medical conference.","Initiated ARC-20 Phase 1/1b for HIF-2a inhibitor AB521 in cancer patients."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":78345000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338747,"accession_number":"0001193125-22-260620","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2022-10-11T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Arcus and Gilead extend share lockup to July 2023, agree to register resale shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lockup on Gilead's Arcus shares extended by one year to July 13, 2023, from original two-year term ending May 2022.","Arcus must file a resale registration statement for Gilead's registrable securities by October 31, 2022.","Amendment executed October 11, 2022; other terms of the Investor Rights Agreement unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356098,"accession_number":"0000950170-22-014263","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2022-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcus Q2 rev $26.8M, net loss $66.6M; ARC-8 PDAC data similar to historical chemo benchmarks; cash $1.27B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and investments $1,271.1M at June 30, 2022, up from $681.3M at Dec 2021, driven by $725M Gilead payment.","Collaboration revenue $26.8M for Q2 2022 vs $9.5M YoY; net loss $66.6M vs $76.0M YoY.","ARC-8 interim analysis for quemliclustat in PDAC: data from randomized cohort similar to historical chemo benchmarks; Arcus and Gilead await mature data in 2023.","Four registrational Phase 3 trials of domvanalimab-based combinations ongoing or planned; ARC-7 topline disclosure expected H2 2022.","AB521 (HIF-2a inhibitor) Phase 1/1b to start Q3 2022; AB801 (AXL inhibitor) nominated; two new molecules expected in clinic in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":44764000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374444,"accession_number":"0000950170-22-011747","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2022-06-16T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Arcus Biosciences revises non-employee director compensation, effective June 14, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual cash retainer set at $45,000 per director; additional retainers for lead independent director ($5,000) and committee chairs/members.","Initial equity award with ~$625,000 grant date fair value, split 2/3 stock options and 1/3 RSUs, vesting over 3 years.","Annual equity award with ~$350,000 grant date fair value, same option/RSU split, vesting fully after 12 months or next annual meeting.","All equity vests fully upon a change in control; new directors do not receive an annual award in the same calendar year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374443,"accession_number":"0000950170-22-008484","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2022-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcus Q1 net loss $68M; ARC-7 domvanalimab arms continue to differentiate","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $1.34B, up from $681M due to $725M from Gilead in Jan 2022; funding into 2026.","Q1 revenue $18M (up from $9.5M YoY); net loss improved to $68M from $72.6M YoY.","Third IA of ARC-7: domvanalimab arms showed meaningful differentiation in ORR and DoR vs anti-PD1 alone; no unexpected safety.","Phase 3 STAR-121 (domvanalimab+zim+chemo vs pembro+chemo) for 1L NSCLC PD-L1 all-comers planned Q4 2022.","R&D expenses $61.2M (down from $66.4M) due to cost-sharing with Gilead; G&A increased to $24M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":18005000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392963,"accession_number":"0000950170-22-001777","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2022-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcus Biosciences reports Q4 net income of $279.4M on Gilead option exercise; cash ~$1.4B post-Gilead payments","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 revenue $354.5M (vs $9.5M Q4 2020) primarily from Gilead license revenue; full-year revenue $382.9M.","Net income Q4 $279.4M vs net loss $51.9M prior year; full-year net income $52.8M vs net loss $122.9M.","Cash, equivalents and investments $681.3M at Dec 31, 2021; plus $725M from Gilead in Jan 2022 = ~$1.4B, funding into 2026.","First patient dosed in PACIFIC-8 Phase 3 (domvanalimab + durvalumab in Stage 3 NSCLC); two more Phase 3 studies planned for 2022.","Data readouts for ARC-7 (domvanalimab/etrumadenant in NSCLC) and ARC-8 (quemliclustat in pancreatic cancer) expected 2H22."],"consensus_eps_estimate":null,"consensus_eps_actual":0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":382882000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":411417,"accession_number":"0000950170-21-005305","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2021-12-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Arcus closes Gilead amendment; receives $725M option fees for 3 programs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed amendment to Option, License and Collaboration Agreement with Gilead on Dec 21, 2021.","Gilead acquires rights to anti-TIGIT (domvanalimab/AB308), adenosine antagonist (etrumadenant), CD73 (quemliclustat).","Gilead to pay $725 million in option fees, expected early Q1 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":411416,"accession_number":"0000950170-21-004749","cik":1724521,"company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","form_type":"8-K","filed_at":"2021-11-18T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Gilead exercises options on three Arcus programs for $725M; co-development and profit sharing","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Gilead paid $725M in option fees to exercise rights to three Arcus programs: anti-TIGIT, adenosine antagonist, and CD73.","Companies will co-develop and equally share US profits/losses; Gilead gets ex-US rights with mid-teens to low-twenties royalties.","Two new research targets added; Gilead can option each for $60M after IND-enabling activities; royalties high-single to low-double digits.","The existing $100M 2022 Continuation Payment will be eliminated if all three programs close; reduced if fewer close.","Transaction subject to HSR antitrust review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2966988826.488528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-11-18T23:59:59+00:00|411416"}